AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Why Astrazeneca (AZN) Dipped More Than Broader Market Today
The latest trading day saw Astrazeneca (AZN) settling at $184.32, representing a -2.17% change from its previous close.
AstraZeneca's Initial Application for Lupus Injection Turned Down by FDA
The company is working with the U.S. regulator to move forward with an updated application, adding a decision is expected in the first half of 2026.
AZN Obesity Pipeline to Get a Boost From Deal With China's CSPC
AstraZeneca deepens its obesity push with an eight-program deal with China's CSPC, securing rights to a once-monthly injectable weight-management pipeline.
AstraZeneca begins trading directly on the NYSE
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares start trading directly on the New York Stock Exchange today, establishing a harmonised global listing along with London and Stockholm. Up to now, US investors could buy the drugmaker's equity via American Depositary Receipts (ADRs), which were listed on the Nasdaq, with each two representing one of the company's ordinary shares.
AstraZeneca is listing in New York, as Big Pharma balances the huge U.S. market with China's tempting innovation
AstraZeneca has announced it's investing $15 billions in China, and said it is partnering with a Chinese biotech to develop weight-loss drugs. The developments come at a critical time for the pharma industry as companies are increasingly looking east for innovation to replace revenue from blockbuster medicines going off patent in the next few years.
AstraZeneca obesity tie-up with CSPC seen as shrewd move
AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) licensing deal on Friday signals a plausible effort by the FTSE 100 group to grab a piece of a booming market for obesity treatments, analysts said, with still plenty to go far despite the market currently being dominated by rivals Novo Nordisk and Eli Lilly. The pharmaceutical group agreed to pay China's CSPC Pharmaceuticals $1.2 billion upfront, with a further $3.5 billion in milestone payments, for rights to eight early-stage weight management and diabetes programmes, including a clinical-ready injectable drug expected to begin trials soon.
AstraZeneca Strikes Multibillion-Dollar Obesity Deal With China's CSPC
The agreement to gain rights outside of China to a portfolio of experimental obesity and diabetes drugs could be valued at billions of dollars.
AstraZeneca strikes $1.2bn obesity drug deal with China's CSPC
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) is paying $1.2 billion up-front to seal a tie-up with a Chinese pharma giant aimed at expanding its weight-loss drug pipeline, as it looks to compete in a fast-growing market against the likes of Novo Nordisk's Ozempic and Eli Lilly's Tirzepatide. The agreement with Hong Kong-listed CSPC Pharmaceutical Group gives the FTSE 100 group global rights outside China to eight drug programmes, including one that is ready to enter human trials.
AstraZeneca sets out $15 billion China investment during Starmer visit
UK drugmaker AstraZeneca said on Thursday it would invest $15 billion in China through 2030 to expand medicines manufacturing and research and development, an announcement made during British Prime Minister Keir Starmer's visit to Beijing.
AstraZeneca the 'top pick' among European pharmas - broker
Analysts at Citi see AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) as 'the top pick' among European pharmaceutical firms. and rate the FTSE 100 stock as a 'buy'.
Why Astrazeneca (AZN) Outpaced the Stock Market Today
Astrazeneca (AZN) closed at $94.23 in the latest trading session, marking a +1.38% move from the prior day.
AstraZeneca to delist from Nasdaq, join NYSE in February
AstraZeneca on Tuesday said it would delist its American Depositary Shares and debt securities from Nasdaq and complete a direct listing of its ordinary shares and debt on the New York Stock Exchange, effective after market close on January 30, 2026.
